The first hydrophobic pocket, P1, of class II MHC has been shown to be an important site of peptide anchoring. Two polymorphisms occur in this pocket in the human class II MHC β chain at position 85 and 86. β85 is usually Val, occasionally Ala, whereas β86 can be Gly or Val. However, Ala85 is found only in conjunction with Val86. The independent effect of the polymorphism at these two positions on the binding of normal and substituted antigenic peptides has never been examined. To do so, three soluble HLA-DR1 variants that contain the naturally occurring combinations of these side chains at these two positions were generated and tested with a panel of influenza matrix peptides varying at anchor P1. DR1 alleles differing only at position 86 are very similar in the binding of a panel of antigenic peptides, indicating that β86 does not substantially influence the peptide binding of DR1. In contrast, DR1 varying only at position β85 differ in their binding of substituted peptides containing Ala, Tyr or Trp at the P1 anchor position. Thus, β85 shows the predominant effect on the P1 anchor side chain preference of the P1 pocket in DR1. This is in contrast to other HLA-DR alleles where β86 has been shown to control the nature of the P1 anchor. These previous data together with our own imply that the role of polymorphism in P1 may be influenced by the contextual framework of the remaining allelic polymorphism.
Introduction
Membrane glycoproteins encoded by MHC class I and II genes play a critical role in specific immune responses; they bind to antigenic peptide fragments and present them for recognition by TCR on the cell surface of T lymphocytes (1) . They are among the most polymorphic of known proteins. The polymorphism of MHC molecules is responsible for MHC restriction of T cell recognition, allorecognition of transplants and MHC-associated diseases (1) (2) (3) (4) . The critical role of MHC polymorphism in T cell recognition is associated with distinct distribution of most polymorphic residues in the peptidebinding grooves of class I and II MHC molecules (5-7).
Therefore, MHC polymorphic residues can regulate T cell recognition by influencing either MHC-peptide or MHC-TCR interactions. The regulatory role of MHC polymorphic residues in MHC-peptide interaction has been suggested by accumulating evidence in recent years. First, it was found that MHC binding to peptides displayed by a phage expression library is allele specific (8) . Second, sequence analysis of peptides eluted from many class I and II molecules revealed that MHC association with endogenous peptides is also allele specific (9) . Third, in vitro peptide binding assays showed that certain MHC polymorphisms directly influence peptide binding to MHC molecules (10, 11) . A clear understanding of the influence of polymorphic residues on peptide binding is necessary for efficient design of peptide vaccines and TCR antagonists.
MHC-peptide binding is dependent on interactions between the side chains of peptide anchor residues and pockets within the peptide binding groove of an MHC molecule. The influence of certain MHC polymorphic residues on peptide binding is associated with their distinct localization in these MHC pockets. The polymorphism could change the stereochemistry of the pocket. For instance, the size of a polymorphic side chain can greatly influence the dimension of the pocket which it is responsible for forming (12) (13) (14) (15) (16) . The stereochemistry of MHC pockets has been correlated with anchor preference of MHC pockets in class I MHC molecules (13, 15, 17) . However, the ability to predict peptide binding from the sequence of an MHC molecule and its structural model remains limited.
For MHC class II molecules, similar polymorphic pockets line the peptide-binding groove. For HLA-DR1, several polymorphic pockets are observed to interact with complementary anchor side chains of influenza hemagglutinin peptide HA306-318 (7). The most prominent hydrophobic pocket is observed to accommodate the side chain of anchor residue Tyr308 near the N-terminus of the peptide. This pocket, referred to as the P1 pocket, contains two polymorphic residues at β85 (Ala/Val dimorphism) and β86 (Gly/Val dimorphism). While the Gly86/Val86 dimorphism is highly conserved and present in most HLA-DR allelic groups, the Ala85/Val85 dimorphism is only present in several DR alleles (18) . The occurrence of Ala85 is always linked to Val86. The effect of Gly86/Val86 dimorphism on the peptide binding has been widely studied and found to influence peptide binding of many DR alleles (19) (20) (21) (22) (23) (24) (25) but not of others (26) (27) (28) . The influence of the Ala85/Val85 dimorphism on peptide binding remains unclear. While it has been shown that DRB1*0101 (βV85G86) and DRB1*0102 (βA85V86) behave differently in binding and presenting certain antigenic peptides for T cell recognition (19, 29) , the exact contribution of each polymorphic residue in defining DR1 peptide binding has not been determined. Because of the importance of β86 in other allelic groups, it has been assumed that β86 would also be the major influence in this case (discussions in 19, 29) .
The study of naturally occurring polymorphism suggests a special role for β85 in DR1 because of the fact that the V85V86 has never been observed as is common with other alleles. The A85V86 combination is also observed in three other cases (18) . In one of these, DRB5*02, the V85V86 combination is also not observed. In order to clearly understand the role of pocket polymorphism in the binding of peptide anchor residues, soluble HLA-DR1 variants containing V85G86, A85V86 and V85V86 in the β chain were generated in insect cells. These three allelic forms represent naturally occurring combinations at these two positions. Their ability to bind a number of naturally occurring peptides was measured and suggested that position 85 could be the major influence. This was studied in more detail by using a panel of influenza matrix peptide analogs containing various hydrophobic amino acid residues at the P1 anchor position.
Methods

Expression of recombinant HLA-DR1 proteins
Soluble human class II HLA-DRB1*0101 (βV85G86), DRB1*0102 (βA85V86) and DR1βV85V86 proteins were generated in Sf9 insect cells using a baculovirus expression system essentially as described (30) . They will be referred to as DR1VG, DR1AV and DR1VV. The soluble DR1 molecules synthesized in insect cells do not contain endogenous peptides in their peptide-binding grooves (31) . Briefly, cDNAs encoding the extracellular domains of DRα and DRβ were amplified using PCR (31) and inserted into a transfer vector, pVL1393. The transfer vectors carrying the truncated DRα or DRβ genes were co-transfected into Sf9 cells with wild-type viral DNA (ACMNPV) using a liposome-mediated method. Recombinant viruses were isolated by limited dilution. The soluble DR proteins were purified from the concentrated media of Sf9 cells co-infected with DRαsol and DRβsol viruses using an immunoaffinity column made with anti-HLA-DR antibody L243-conjugated Protein A beads (32) . The purified DR1 proteins migrated at predicted sizes of α and β subunits (33 and 29 kDa) by SDS-PAGE. They can be recognized by SG520 (α), TAL 15.1 (β1) and the antibody used for affinity purification, L243, but not by control antibodies such as DA6.147, which binds to a cytoplasmic domain of DR, DR3-specific antibody NDS9 and DR4-specific antibody 13F10. The peptide-binding capacity of the purified DR1 proteins was confirmed by their ability to bind to the DR1-restricted influenza matrix peptide MP19-31, specifically.
Peptides
The following synthetic peptides were used in our study: influenza hemagglutinin HA306-318, PKYVKQNTLKLAT; tetanus toxin TT830-843, QYIKANSKFIGITE; rye grass pollen Lol Pl191-210, ESWGAVWRIDTPDKLTGPFT; influenza matrix peptide, MP19-31, PLKAEIAQRLEDV; and MP19-31 analogs bearing conservative substitutions of the P1 anchor residue Leu with Ala, Val, Ile, Phe, Tyr and Trp. These peptides were synthesized by standard solid-phase methods and purified by HPLC. They were also labeled with FITC at their N-termini, purified by reversed-phase HPLC and the purity confirmed by mass spectrometry.
Peptide binding assays Indicated amounts of purified HLA-DR1 proteins were used in 50 µl binding mixtures with indicated amounts of labeled and/or unlabeled peptides. The binding conditions were 37°C in PBS, with 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM iodoacetamide and 3 mM NaN 3 at pH 7.2. After incubation for 24 h, the binding mixtures were resolved on native PAGE to separate the bound from the unbound peptides as described (33) or on SDS-PAGE to measure SDS-stable binding. These conditions are sufficient for quantitative peptide binding. Detection of the FITC-labeled peptides after electrophoresis was performed using the FluorImager 575 (Molecular Dynamics, Sunnyvale, CA) and fluorescence quantitated using ImageQuant (Molecular Dynamics) software.
Native PAGE or SDS-PAGE
For native PAGE, peptide binding mixtures were mixed with sample-loading buffer without SDS and resolved on 12% acrylamide PAGE slab gels (7ϫ7ϫ0.075 cm) as described (34) . For SDS-PAGE, the peptide binding mixtures were mixed with SDS-PAGE sample buffer (34) containing a final concentration of 1% SDS without boiling before application to 12% acrylamide SDS-PAGE slab gels. Low mol. wt range protein standards (BioRad, Hercules, CA) or FITC-labeled protein standards (Sigma, St Louis, MO) were used as size markers. After the electrophoresis, gels were stained with Coomassie brilliant blue R-250 to detect the presence of proteins or scanned using the FluorImager 575 to detect the FITC emission of labeled peptides.
Molecular imaging
PDB files of crystallographic data for DR1 co-crystallized with the influenza hemagglutinin peptide (7) were downloaded from the Brookhaven Repository. DR3 and CLIP data were sent by Dr Gosh (35) . Residues in the first MHC pocket and on the peptide were mutated using SYBYL (Tripos, St Louis, MO), and energy minimization was performed using the SYBYL BIOPOLYMER MINIMIZE module with default values. Water accessible surfaces (Connolly surface) were generated using InSightII (Biosym, San Diego, CA). InSightII-generated molecular images were saved as .TIF files.
Results
Binding of naturally occurring antigenic peptides indicates that β85 rather than β86 is important for anchor residue interaction
Soluble HLA-DR1 variants DR1Val85Val86, DR1Val85Gly86 (DRB1*0101) and DR1Ala85Val86 (DRB1*0102), from here on referred to as DR1VG, DR1AV and DR1VV, were generated in Sf9 insect cells. They were used to determine the effect of individual polymorphism at the residues β85 and β86 in the binding of peptides to DR1 molecules. The major advantage of insect-cell-derived recombinant molecules is that they are synthesized with the peptide binding groove predominantly unoccupied by endogenous peptides (31) . Four wellcharacterized DR1-binding antigenic peptides were tested: TT830-843 (36), HA306-319 (7), Lol Pl191-210 (37) and MP19-31 (29) .
As shown in Fig. 1 , FITC-labeled TT830-843, HA306-318 and Lol Pl191-210 bound at similar levels to the DR1VV and DR1VG variants, but little, if at all, to the DR1AV variant. The data are given in fluorescence binding units. The variations observed between the DR1VV and DR1VG are probably due to the differences in the ability of equimolar amounts of the preparations (100 nM) to functionally bind peptide. In contrast, similar levels of binding to all three DR1 variants were observed with the MP19-31 peptide (Fig. 1) . The binding of MP19-31 to the DR1AV variant shows that this DR1 preparation is functional. The specificity of the FITC-labeled peptide binding is shown by competition with excess amount of unlabeled peptides (Fig. 1, filled columns) .
In these experiments, DR1AV is considerably different from DR1VV in the binding of FITC-labeled TT830-843, HA306-318 and Lol Pl191-210 (Fig. 1) , whereas DRVV and DR1VG act in a similar manner. Therefore, the peptide binding of DR1 molecules is restricted by the β85 but not the β86 polymorphism, suggesting a differential role of β85 and β86 polymorphism in the peptide binding.
The three peptides, whose binding to DR1 is dramatically influenced by the β85 polymorphism, contain large aromatic residues at the P1 anchor position Tyr831 for TT830-843 (29, 38) , Tyr308 for HA306-318 (7) and Trp197 or Trp193 for Lol Pl191-210; whereas the single peptide, MP19-31, whose binding is not affected substantially by the β85 dimorphism, contains a smaller aliphatic residue (Leu20) at the same position (29, 30) . This strongly suggested that the influence of the β85 dimorphism on peptide binding to DR1 could be linked to the nature of the P1 anchor side chains of the peptides.
The β85 Ala/Val dimorphism rather than the β86 Val/Gly dimorphism affects allowable substitutions in the P1 anchor residue
To further investigate the relationship between the polymorphic residues and anchor P1, we utilized the observation that MP peptide can bind to all three DR1 forms. The levels of binding of MP19-31 to each of the DR1 variants was similar over a range of peptide concentrations, indicating that the affinity of MP19-31 binding to each of the DR1 variants was similar (Fig. 2) . Binding was at a plateau for all three DR1 variants by 600-800 nM peptide.
To test whether the influence of the β85 dimorphism on peptide binding to DR1 was dependent on the identity of the P1 anchor residue within the peptide in a controlled fashion, MP19-31 analogs were generated that contained Ala, Val, Ile, Phe, Tyr or Trp instead of Leu at the P1 anchor position. As shown in Fig. 3, DR1VG and DR1VV bound MP19-31 analogs with Val, Ile, Phe, Tyr or Phe but not Ala at the P1 anchor position. In contrast, DR1AV bound MP19-31 analogs with Ala, Val, Ile and Phe but not Tyr or Trp at the P1 anchor position. It should be pointed out that the peptides were at 1 µM, which is past the binding plateau of the Leu anchor peptide for all three DR1 variants. Thus, a DR1 pocket with Val at β85 accommodated all aromatic and all but the smallest aliphatic amino acid side chains at the P1 peptide anchor residue. On the other hand, a DR1 pocket with Ala at β85 accommodated all aliphatic and the smallest aromatic but not the larger aromatic amino acid side chains at the P1 peptide anchor residue.
These results are summarized in Fig. 4 . Figure 4 also includes the outcome of binding studies using a Gly-substituted peptide which was used as a negative control in a separate experiment. Polymorphism at β86 does not affect the nature of the allowed anchor nor influence peptide binding to DR1. The effect of the β85 polymorphism on peptide binding is to restrict binding to peptides with less bulky side chains at the P1 anchor residue and allow binding of peptides with the small side chain, Ala, at the anchor position. A peptide with only hydrogen as a side chain at position 20, Gly, would not bind.
The β85 Ala/Val dimorphism, not the β86 Ala/Val dimorphism, influences SDS stability of DR1 binding to MP19-31
The analyses of peptide binding presented above utilized non-denaturing conditions which avoided the action of detergents. It is well known that the presence of SDS can affect the binding of certain peptides. Therefore, to further test the influence of the β85 and β86 polymorphic residues in the DR1-peptide interaction, we investigated the effect of the β85 and β86 polymorphism on SDS stability of DR1 binding to the MP19-31 peptide. MHC class II-peptide complexes can be separated into SDS-stable or -labile complexes according to their sensitivity to α-β chain dissociation induced by SDS at room temperature (39) . Although the mechanism for the SDS stability of class II MHC-peptide complexes is not clear, the formation of SDS-stable or -labile complexes does represent differences in the nature of class II MHC-peptide interactions. DR1 variants were incubated with FITC-labeled peptides at 37°C for 24 h. The binding mixtures were then analyzed by native PAGE (Fig. 5A ) to measure total binding and by SDS-PAGE (Fig. 5B) to measure SDS-stable binding. The percentage of SDS-stable binding was used to compare the stability of DR1-peptide complexes. While Both DR1VV and DR1VG form a similar percentage of SDS-stable complexes when they bind to MP19-31 peptides, DR1AV forms a much higher percentage of SDS-stable complexes than DR1VV (Fig. 5C) , indicating that the A85/V85 dimorphism, not the V86/G86 dimorphism, plays a major role in regulating the SDS stability of peptide binding to DR1 molecules.
Molecular modeling of position β85 in DR1 alleles
The availability of the DR1 X-ray crystal structure allows one to determine how the polymorphisms at β85 and β86 could affect the structure of the DR molecule. With minimal changes all three polymorphic forms of DR1 used in these experiments can be modeled. The VG allele was converted to the VV allele in the presence of bound HA peptide and energy minimization performed. The resulting structure was compared to the VV pocket of DR3, whose structure had been solved (35) . The structure of DR1VV in this region was identical to that of the DR3 crystal. At this point V85 was changed to A85 and the same procedure followed. A number of modifications to the peptide were made for each DR1 allele. The N-terminal anchor residue of the HA306-318 peptide (Tyr) was changed to Trp followed by energy minimization. Independently, the entire HA306-318 peptide was substituted for the MP19-31 peptide followed by minimization. The modeled P1 anchor was then changed from Leu to Trp. The position of Trp in either the HA or MP19-31 peptide was very similar within the pocket.
A Connolly water-accessible surface was generated using the DR1 alleles from which the N-terminal peptide residues up to and including the first anchor residue had been subtracted. The surface was generated for all atoms within a 10 Å radius of the amide oxygen in residue 85. To help visualize the effect of the polymorphism on the pocket structure, the peptide anchor Trp residue was redisplayed as a stick structure (Fig. 6) . Trp was chosen because it represents a side chain which abrogates binding to the DR1AV variant. The perspectives from slightly above the plane of the peptide show the round entrance to the pocket in the VG and VV forms ( Fig. 6A and B) . This entrance is completely blocked by the amide nitrogen of the Trp residue when the van der Waals' projection of the nitrogen is used (not shown). The opening to the pocket is much wider in the AV form (Fig. 6C) . It is easy to see that the side of the pocket is lower in the AV form, exposing more of the hydrophobic side chain of the anchor Trp residue. The models show that the nature of the residue at β85 strongly influences the dimensions of the top opening and side of the pocket that faces outward towards the solvent.
Discussion
The present study provides new insights into class II MHCpeptide interactions, taking into account the stereochemistry of a polymorphic peptide binding pocket and its interactions with complementary peptide anchor residues. Using soluble DR1 variants differing at two polymorphic pocket residues, β85 and β86, we evaluated the effect of the polymorphism on DR1-peptide interactions. We changed each residue independently to the other possibility which is naturally observed in DRβ chains, eliminating possible artifacts due to improper folding or pairing that can be expected if unusual polymorphic combinations are generated. Therefore, the combination A85G86 was not used as it never occurs in nature. The effect of the polymorphism at β85 has never been investigated independently, as previous work has used alleles in which both β85 and β86 were different (19, 29) .
Our results revealed that the Ala/Val dimorphism at position 85 of the β chain significantly affected the binding of HLA-DR1 to antigenic peptides TT830-843, HA306-318, Lol Pl191-210 as well as MP19-31 bearing Ala, Tyr or Trp at the P1 anchor position. Changing β86 while holding β85 constant had no effect. Thus, the β85 dimorphism regulates the peptide binding specificity of HLA-DR1 molecules. These direct binding assays were performed at concentrations (1 µM) where the Leu peptide was saturating for all three DR1 variants. Furthermore, at that concentration each peptide could bind to at least one of the variants. Thus, it is unlikely that further increasing the concentration of the Ala, Tyr or Trp peptides would make them bind to the respective variants. Because we did not perform titration analysis for all the variants and all the peptides, it is possible that a smaller effect may also be observed for β86; however, the predominant effect is that of β85. Further studies are required to show whether the β85 polymorphism also regulates the peptide binding of other HLA-DR alleles. We predict that what has been observed here for DR1 will also be true of other DR molecules where alleles with the AV and not VV polymorphism are observed, such as DRB5.
The observation that β85 and not β86 restricts the nature of the anchor residue is surprising in the light of the importance of β86 in other studies utilizing other DR alleles (19) (20) (21) (22) (23) (24) (25) . We interpret this to show that the polymorphism at one pocket regulates peptide binding to HLA-DR molecules in the context of other polymorphic residues. This is in keeping with the observation that the β86 dimorphism was not very influential in the peptide binding of certain HLA-DR molecules (26) (27) (28) . Therefore, it is very possible that the effect of the β86 dimorphism is restricted by allelic differences, supporting a model wherein MHC polymorphic residues regulate peptide binding in a concerted manner.
The added effect of detergent upon the stability of peptide complexes formed with the different DR1 variants also showed the pronounced effect of the dimorphism at position 85. Although our DR1 variants bind to MP19-31 peptide with a similar high affinity, DR1AV was found to form a much higher percentage of SDS-stable complexes with MP19-31 peptide than DR1VV and DR1VG. Similar results were also observed for the invariant chain-derived CLIP peptide binding to DR1 (40) . Therefore, our data indicated that the β85 Ala/Val dimorphism plays a major role and the β86 Gly/Val dimorphism plays a minor role in regulating the SDS stability of DR1-peptide complexes. This is again in contrast to a report using DRB1*1101 and DRB1*1104 alleles wherein the β86 Gly/Val dimorphism played an important role in determining the SDS stability of peptide-MHC complexes formed (41) . Therefore, MHC polymorphic residues may also act in concert to regulate detergent stability of DR-peptide complexes.
Inspection of the published DR1 X-ray crystal structure suggests an explanation for our observation that the dimorphism at position 85 more strongly influences the binding of peptide ligands to DR1 than does the dimorphism at position 86. Although the side chain of the amino acid at position 86 controls the depth of pocket in which it is located, we predict the extra depth generated when Gly instead of Val is at this position remains unused or contains a water molecule. This can be seen when Trp is substituted for Tyr in the original DR1 crystal structure. Substituting Val at 86 while maintaining Val at 85 leaves the pocket sufficiently deep to allow Trp anchoring. However, the effect of changing Val85 to Ala removes a part of the pocket wall that faces the solvent exterior as well as part of the top opening of the pocket. This may allow solvent (and detergent) access to the pocket's hydrophobic core, resulting in destabilization of the peptide-MHC complex. Anchor residues with greater flexibility or that are shorter may be able to turn their side chains or sink deeper into the pocket so as to allow the amide bond of the anchor residue to block the larger opening to the exterior created by the Ala85 residue. The nature of the peptide residues flanking the anchor residue may also be important in this regard.
The relative importance of residue 85 in the context of DR1 and the converse lack of evidence for a predominant role for residue 86 may explain why DR1 does not have a widely occurring VV form, as this polymorphism would offer no advantage over VG. As mentioned previously, the lack of a strong position 86 effect in DR1 together with the welldocumented effect of position 86 in the context of other DR alleles indicates that polymorphic positions may act in a concerted manner. A prime candidate for another polymorphic position that may play a role is β13. Two of three allelic groups in which AV is frequently present, DRB1*01 and DRB5*02, have bulky aromatic groups Phe or Tyr at β13. In most other alleles, this position is polar/charged Ser, His, Gly or Arg. Thus, we would hypothesize that the geometry of the peptide backbone, as influenced by polymorphism at position 13, may influence the role of position 86. In those cases where this is minimized, the AV polymorphism at 85 has been selected to increase variability in peptide binding. This supports the notion that occurrence of MHC polymorphism is due to evolutionary selection pressure that originated from various infectious agents (42) . The β85 polymorphism would increase the human class II MHC molecule's versatility to present a wide array of peptides.
The experiments described here and our conclusions based on examination of the crystal structure indicate the importance of position 85, which is located at the end of the peptide binding groove, in determining the stability of the class II MHC-peptide complex. This part of the class II molecule may be a primary site involved in such effects as SDS stability, conformational change and intrinsic or DM-mediated peptide release.
